Health officials have approved a new treatment for pinworms that can help some people with chronic chest pain, but they have also approved a more potent one that could lead to more serious side effects.
According to the FDA’s website, the pinworm treatment, called Reese’s Pinworm Medicine, is a combination of two medications: a drug to treat the disease and an opioid antagonist, which blocks pain receptors.
The pinworm disease is caused by the worm’s bite and can cause fever, muscle aches, headaches, and pain in the legs, abdomen, arms, and back.
Doctors prescribe pinworm medications for patients who have trouble getting the worms out of the body.
The medications are usually prescribed to relieve chronic chest pains and inflammation.
“These medications are not FDA approved, and their effectiveness is not well understood,” said Dr. Michael A. DeGrazia, an infectious disease specialist at Children’s Hospital Los Angeles, in a press release.
“Patients should discuss the use of these medications with their physician or nurse practitioner and with a healthcare provider.”
The Pinworm Treatment was approved by FDA’s Food and Drug Administration (FDA) on Nov. 25.
The agency’s drug reviewer said the drug had been tested and found to be safe and effective in treating chronic chest disease.
The FDA’s decision to approve Reese, however, has raised questions about whether the company can sell the medication in the United States.
The company has yet to release the drug in the U.S. and the FDA has not issued a formal order approving the drug for sale, according to the release.
“The FDA will review the information submitted by the manufacturer and consider whether there are any safety concerns related to this drug,” the agency said in the release, adding that it will provide updates as soon as possible.
A spokeswoman for Reese declined to comment.
The Pinworms are found in the genus Raphidophis and are transmitted to humans through fleas, and pinworms can cause serious illness.
They can cause infection and lead to severe illness.